ScinoPharm Taiwan Ltd
TWSE:1789
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| TW |
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
19.1B TWD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
978.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
571.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
286B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.8B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
226.6B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
213.9B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.1B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.8B USD |
Loading...
|
Market Distribution
| Min | -22 082.4% |
| 30th Percentile | 1% |
| Median | 5.3% |
| 70th Percentile | 11.1% |
| Max | 1 580% |
Other Profitability Ratios
ScinoPharm Taiwan Ltd
Glance View
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for ScinoPharm Taiwan Ltd is 6%, which is below its 3-year median of 9%.
Over the last 3 years, ScinoPharm Taiwan Ltd’s Net Margin has decreased from 10.3% to 6%. During this period, it reached a low of 6% on Oct 30, 2025 and a high of 11.8% on Jun 30, 2024.
